ライフサイエンスコーパス: hepatitis B surface antigen

1 e gold sensor surface and post modified with hepatitis B surface antigen.

2 in HCC deaths from screening in carriers of hepatitis B surface antigen.

3 vitro were observed in response to RTS,S or hepatitis B surface antigen.

4 s, syphilis, human T lymphocyte virus I, and hepatitis B surface antigen.

5 he TDF+placebo group; no patient had loss of hepatitis B surface antigen.

6 y 1 patient (0.7%) in the FTC/TDF group lost hepatitis B surface antigen.

7 33 patients and staff who were positive for hepatitis B surface antigen, 30 (91%) showed complete nu

8 tis B e antigen (94% vs. 40%; P < 0.001) and hepatitis B surface antigen (71% vs 8.3%; P < 0.001).

9 ble HBV DNA in plasma and loss of detectable hepatitis B surface antigen after cessation of therapy.

10 eover, HepG2/NTCP cells secreted very little hepatitis B surface antigen after infection with cell cu

11 was defined by presence of serum antibody to hepatitis B surface antigen among children aged 2 years.

12 f a binary vector containing a gene encoding hepatitis B surface antigen and a gene encoding the kana

13 tor high-risk children at 1 year of age with hepatitis B surface antigen and anti-hepatitis B to iden

14 onal hepatocyte expansion, and expression of hepatitis B surface antigen and core antigen in liver ti

15 Strong liver expression of hepatitis B surface antigen and hepatitis B core antigen

16 nations and biochemical studies were normal, hepatitis B surface antigen and hepatitis B core antigen

17 all patients were taking 3TC or FTC and were hepatitis B surface antigen and hepatitis B e antigen po

18 ected on pregnant women testing positive for hepatitis B surface antigen and on their infants, childr

19 r hepatitis B viral infection by testing for hepatitis B surface antigen and the antibody to hepatiti

20 After 2 days, hepatitis B surface antigen and the antigenic forms of L

21 e identified 21,419 veterans with a positive hepatitis B surface antigen, and 97% of patients had ala

22 tested for antibodies to hepatitis C virus, hepatitis B surface antigen, and IgM antibodies to hepat

23 ducation, tobacco smoking, alcohol drinking, hepatitis B surface antigen, and/or anti-hepatitis C vir

24 >6 months of age were tested for antibody to hepatitis B surface antigen (anti-HBs) 22 years later.

25 d subjects seropositive for both antibody to hepatitis B surface antigen (anti-HBs) and anti-HBc (13

26 B vaccine, and 94% demonstrated antibody to hepatitis B surface antigen (anti-HBs) at levels > or =

27 ollected in 2001 were tested for antibody to hepatitis B surface antigen (anti-HBs) by AUSAB enzyme-l

28 article vaccine) in inducing protective anti-hepatitis B surface antigen (anti-HBs) concentrations in

29 s B core antigen (anti-HBc), and antibody to hepatitis B surface antigen (anti-HBs) in 1214 serum sam

30 emic areas have reported loss of antibody to hepatitis B surface antigen (anti-HBs) in a high proport

31 e the direct detection of antibodies against hepatitis B surface antigen (anti-HBs) in clinical serum

32 ude and duration of the antibody response to hepatitis B surface antigen (anti-HBs) induced by the HB

33 Persons were tested for antibody to hepatitis B surface antigen (anti-HBs) levels 30 years a

34 icting studies about whether the antibody to hepatitis B surface antigen (anti-HBs) protects against

35 HBsAg) clearance with or without antibody to hepatitis B surface antigen (anti-HBs) seroconversion.

36 years, cumulative persistence of antibody to hepatitis B surface antigen (anti-HBs) was 85%, and cumu

37 Concentrations of antibody to hepatitis B surface antigen (anti-HBs) were determined b

38 rom OBI carriers with or without antibody to hepatitis B surface antigen (anti-HBs) were expressed in

39 children (50%) had undetectable antibody to hepatitis B surface antigen (anti-HBs), and only 8 (13%)

40 chronic (current) infection; and antibody to hepatitis B surface antigen (anti-HBs), indicative of im

41 Antibody to hepatitis B surface antigen (anti-HBs), markers of HBV i

42 fter the chimpanzees developed antibodies to hepatitis B surface antigen (anti-HBs), they were challe

43 s B surface antigen (HBsAg), and antibody to hepatitis B surface antigen (anti-HBs).

44 presence of any of HBV serological markers (hepatitis B surface antigen, anti-hepatitis B core antib

45 oking, serum alanine aminotransferase, serum hepatitis B surface antigen, anti-hepatitis C virus anti

46 ng, elevated alanine aminotransferase, serum hepatitis B surface antigen, anti-hepatitis C virus posi

47 ent, and immunoprecipitation with monoclonal hepatitis B surface antigen antibodies (anti-HBs), indic

48 negative, over half (52.9%) had antibody to hepatitis B surface antigen antibody levels of <10 mIU/m

49 Practice Advice 2: Clinicians should screen (hepatitis B surface antigen, antibody to hepatitis B cor

50 og10 decrease in levels of serum HBV DNA and hepatitis B surface antigen, as well as liver HBV RNA, w

51 munodeficiency virus, hepatitis C virus, and hepatitis B surface antigen before transfusion.

52 t the N terminus of the pre-S1 region of the hepatitis B surface antigen between residues 17 and 21,

53 or both human immunodeficiency virus 1/2 and hepatitis B surface antigen by Western blot and neutrali

54 from 16 Chinese patients, half of whom were hepatitis B surface antigen carriers.

55 IL28B genotype was also associated with hepatitis B surface antigen clearance (HR, 3.47 for AA v

56 roconversion (RR = 2.1, 95% CI 1.4-3.3), and hepatitis B surface antigen clearance (RR = 5.8, 95% CI

57 ersion), along with HBeAg seroconversion and hepatitis B surface antigen clearance during long-term f

58 ppression (RR = 1.4, 95% CI 1.1-1.8) but not hepatitis B surface antigen clearance or seroconversion.

59 of seroconversion (hepatitis B e antigen or hepatitis B surface antigen) compared to single drug the

60 HBs titers necessary to minimize the risk of hepatitis B surface antigen detectability were >500 IU/L

61 se of the absence of a documented history of hepatitis B surface antigen for at least six months.

62 hepatitis B infection (negative results for hepatitis B surface antigen) for findings associated wit

63 to hepatitis B core antigen, and antibody to hepatitis B surface antigen) for HBV in high-risk person

64 Variants of hepatitis B surface antigen have been described in diffe

65 add-on led to significantly more decline in hepatitis B surface antigen, HBeAg, and HBV DNA (all P <

66 atitis B virus (HBV) DNA (</=2000 IU/mL) and hepatitis B surface antigen (HBsAg) (<1000 IU/mL) have b

67 odds ratio for prevalent diabetes comparing hepatitis B surface antigen (HBsAg) (+) to HBsAg (-) par

68 EPI with hepatitis B surface antigen (HBsAg) and a synthetic pept

69 chronic HBV infection was assessed by serum hepatitis B surface antigen (HBsAg) and AFB1 exposure by

70 By using this strategy, we investigated the hepatitis B surface antigen (HBsAg) and alpha-fetoprotei

71 Rates of prevalence of hepatitis B surface antigen (HBsAg) and antibodies again

72 o were born after July 1987 were assayed for hepatitis B surface antigen (HBsAg) and antibodies to HB

73 studies had to report seroprevalence of both hepatitis B surface antigen (HBsAg) and antibodies to HC

74 -1-positive subjects who tested negative for hepatitis B surface antigen (HBsAg) and antibody to HBsA

75 n patients with cancer who test positive for hepatitis B surface antigen (HBsAg) and are undergoing c

76 Serologic HBV markers, including hepatitis B surface antigen (HBsAg) and e antigen (HBeAg

77 in blood donors is achieved by screening for hepatitis B surface antigen (HBsAg) and for antibodies a

78 Screening should include both hepatitis B surface antigen (HBsAg) and hepatitis B core

79 n be predicted by on-treatment monitoring of hepatitis B surface antigen (HBsAg) and hepatitis B viru

80 selected samples for quantitative levels of hepatitis B surface antigen (HBsAg) and hepatitis delta

81 describe the binding to MIF of two peptides, hepatitis B surface antigen (HBsAg) and insulin B (InsB)

82 tains full-length HDV RNA and an envelope of hepatitis B surface antigen (HBsAg) and is not different

83 Therefore, the interaction of hepatitis B surface antigen (HBsAg) and KCs, and possibl

84 The first gene encoded the hepatitis B surface antigen (HBsAg) and the second encod

85 In ethanol-fed mice, the levels of hepatitis B surface antigen (HBsAg) and viral DNA in ser

86 The kinetics of hepatitis B surface antigen (HBsAg) are predictive in HB

87 om a major hospital in Ghana with a range of hepatitis B surface antigen (HBsAg) assays.

88 cipients of livers from donors without serum hepatitis B surface antigen (HBsAg) but with antibody to

89 protein design to improve expression of the hepatitis B surface antigen (HBsAg) by attempting to mim

90 Mutations may also impact the detection of hepatitis B surface antigen (HBsAg) by commercial assays

91 hepatitis B e antigen (HBeAg)-seropositive, hepatitis B surface antigen (HBsAg) carrier children, wh

92 n superimposed on chronic hepatitis B or the hepatitis B surface antigen (HBsAg) carrier state.

93 described instances of reactivation occur in hepatitis B surface antigen (HBsAg) carriers with inacti

94 t common risk factors were cohabitation with hepatitis B surface antigen (HBsAg) carriers, intravenou

95 In 118 previous hepatitis B surface antigen (HBsAg) carriers, low-level

96 of 547 children aged 1-16 years who were not hepatitis B surface antigen (HBsAg) carriers.

97 A post-treatment response was defined as hepatitis B surface antigen (HBsAg) clearance with or wi

98 reatment course, and a higher likelihood for hepatitis B surface antigen (HBsAg) clearance.

99 Point-of-care tests for hepatitis B surface antigen (HBsAg) could be an ideal to

100 Among 2334 RA patients who had available hepatitis B surface antigen (HBsAg) data, 123 patients p

101 Plasma levels of hepatitis B surface antigen (HBsAg) declined for only a

102 Oral immunogenicity of recombinant hepatitis B surface antigen (HBsAg) derived from yeast (

103 cent (12 of 60) of the AHBV-ALF group had no hepatitis B surface antigen (HBsAg) detectable on admiss

104 Loss of hepatitis B surface antigen (HBsAg) during a year of ora

105 kinetics of hepatitis delta virus (HDV) and hepatitis B surface antigen (HBsAg) during interferon-al

106 cohort of women after they were screened for hepatitis B surface antigen (HBsAg) during pregnancy.

107 inical trial evaluated the immunogenicity of hepatitis B surface antigen (HBsAg) expressed in potatoe

108 Hepatitis B surface antigen (HBsAg) expression cassettes

109 clearance of hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg) from serum is less o

110 nic HBV infection and sustained clearance of hepatitis B surface antigen (HBsAg) from serum.

111 , R21 particles are formed from a single CSP-hepatitis B surface antigen (HBsAg) fusion protein, and

112 Alexander cells have integrated the hepatitis B surface antigen (HBsAg) gene and quantitativ

113 liver lesions of transgenic mice bearing the hepatitis B surface antigen (HBsAg) gene of hepatitis B

114 Here, we investigated hepatitis B surface antigen (HBsAg) genetic features und

115 Patients with lower levels of hepatitis B surface antigen (HBsAg) have higher chances

116 Portal vein infusion of an rSV40 expressing hepatitis B surface antigen (HBsAg) in a naive Gunn rat

117 The age-specific seroclearance pattern of hepatitis B surface antigen (HBsAg) in chronic hepatitis

118 a showing oral immunogenicity of recombinant hepatitis B surface antigen (HBsAg) in preclinical anima

119 Transgenic mice that express hepatitis B surface antigen (HBsAg) in their liver and d

120 amuscular injection, a TAP fragment encoding hepatitis B surface antigen (HBsAg) induced anti-HBsAg a

121 which the circumsporozoite protein fused to hepatitis B surface antigen (HBsAg) is expressed togethe

122 Seroclearance of hepatitis B surface antigen (HBsAg) is one of the most i

123 onstituted HepG2 cells, although very little hepatitis B surface antigen (HBsAg) is produced.

124 The a determinant of hepatitis B surface antigen (HBsAg) is the most critical

125 elevated alanine aminotransferase, although hepatitis B surface antigen (HBsAg) kinetics may help pr

126 This study investigated the role of serum hepatitis B surface antigen (HBsAg) levels and establish

127 S/S gene variability has any impact on serum hepatitis B surface antigen (HBsAg) levels and to analyz

128 HBV RNA, HBV DNA, and hepatitis B surface antigen (HBsAg) levels as well as pr

129 inetics of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) levels during flares

130 e profile and clinical significance of serum hepatitis B surface antigen (HBsAg) levels during long-t

131 In patients with low viral loads, higher hepatitis B surface antigen (HBsAg) levels have been sho

132 The kinetics of hepatitis B surface antigen (HBsAg) levels preceding spo

133 On-treatment levels of hepatitis B surface antigen (HBsAg) may predict response

134 e use of organs from marginal donors who are hepatitis B surface antigen (HBsAg) negative and hepatit

135 B e antigen (HBeAg) and antibody (anti-HBe), hepatitis B surface antigen (HBsAg) or antibody (anti-HB

136 hepatitis B core antibody (anti-HBc) without hepatitis B surface antigen (HBsAg) or hepatitis B surfa

137 h acute HBV infection until the clearance of hepatitis B surface antigen (HBsAg) or the development o

138 asured in cells, extracellular vesicles, and hepatitis B surface antigen (HBsAg) particles of hepatom

139 e kidneys into recipients who are themselves hepatitis B surface antigen (HbsAg) positive with approp

140 All were hepatitis B surface antigen (HBsAg) positive, and 61% ha

141 A total of 42 hepatitis B surface antigen (HBsAg) positive, human immu

142 All eight patients enrolled were hepatitis B surface antigen (HBsAg) positive; their HBV

143 cted persons, persons born in countries with hepatitis B surface antigen (HBsAg) prevalence of more t

144 isporivir and NIM811) on HBV replication and hepatitis B surface antigen (HBsAg) production in cell l

145 rus (HBV) vaccine is based on three doses of hepatitis B surface antigen (HBsAg) protein.

146 g of adult community-based screening using a hepatitis B surface antigen (HBsAg) rapid test and subse

147 In one patient, hepatitis B surface antigen (HBsAg) recurred four months

148 Model fits show that hepatitis B surface antigen (HBsAg) remained stable afte

149 utic ETV at the time of HBV reactivation and hepatitis B surface antigen (HBsAg) reverse seroconversi

150 d communities in western Gambia were offered hepatitis B surface antigen (HBsAg) screening via a poin

151 Hepatitis B surface antigen (HBsAg) seroclearance has be

152 morphisms (SNPs) at HLA-DP and IL28B loci on hepatitis B surface antigen (HBsAg) seroclearance in chr

153 ed with HCV-monoinfected patients and a high hepatitis B surface antigen (HBsAg) seroclearance rate.

154 The cumulative rates of hepatitis B surface antigen (HBsAg) seroclearance were 9

155 Native hepatitis B surface antigen (HBsAg) spontaneously assemb

156 cipants, 603,585 had baseline data for serum hepatitis B surface antigen (HBsAg) status and were incl

157 cept for mothers who had positive or unknown hepatitis B surface antigen (HBsAg) status.

158 t after adjustment for covariates, including hepatitis B surface antigen (HBsAg) status.

159 Hepatitis B surface antigen (HBsAg) subtypes and DNA seq

160 le HBV viral load, 7 had positive results on hepatitis B surface antigen (HBsAg) testing and had an u

161 The 90-day hepatitis B surface antigen (HBsAg) testing rate was 28.

162 or Disease Control and Prevention recommends hepatitis B surface antigen (HBsAg) testing to identify

163 Simple hepatitis B surface antigen (HBsAg) tests may facilitate

164 plasmid expression vectors for lacZ and the hepatitis B surface antigen (HBsAg) to intact skin induc

165 Hepatitis D virus (HDV) requires hepatitis B surface antigen (HBsAg) to propagate infecti

166 Intradermal immunization of mice against hepatitis B surface antigen (HBsAg) using a novel real-t

167 Loss of hepatitis B surface antigen (HBsAg) usually indicates th

168 The serum gradient of hepatitis B surface antigen (HBsAg) varies over time aft

169 At birth, hepatitis B surface antigen (HBsAg) was detected in 20%

170 Serum HGV RNA and hepatitis B surface antigen (HBsAg) were assessed in 127

171 Immunoglobulin G (IgG) and Hepatitis B surface Antigen (HBsAg) were quantitatively

172 Samples positive for hepatitis B surface antigen (HBsAg) were tested for HBsA

173 ies to hepatitis C virus antigen (anti-HCV), hepatitis B surface antigen (HBsAg), and antibodies to h

174 body to hepatitis B core antigen (anti-HBc), hepatitis B surface antigen (HBsAg), and antibody to hep

175 nts of serum alanine aminotransferase (ALT), hepatitis B surface antigen (HBsAg), and HBV DNA monthly

176 eponema pallidum, and hepatitis B, tests for hepatitis B surface antigen (HBsAg), and polymerase chai

177 The seromarkers hepatitis B surface antigen (HBsAg), anti-HCV, and serum

178 Angeles County for the presence in serum of hepatitis B surface antigen (HBsAg), antibodies to HBsAg

179 and 72 age-matched controls were tested for hepatitis B surface antigen (HBsAg), antibodies to hepat

180 We measured hepatitis B surface antigen (HBsAg), antibody to hepatit

181 All were tested for hepatitis B surface antigen (HBsAg), antibody to hepatit

182 d HBV DNA from the serum; 1 went on to clear hepatitis B surface antigen (HBsAg), before transplantat

183 ultiplex cytokine measurements, quantitative hepatitis B surface antigen (HBsAg), HBeAg levels, HBV g

184 reactivation and hepatitis we identified all hepatitis B surface antigen (HBsAg), HBV DNA, and alanin

185 t of CHB based on age-specific prevalence of hepatitis B surface antigen (HBsAg), hepatitis B e antig

186 6 months thereafter, we tested for HBeAg and hepatitis B surface antigen (HBsAg), hepatitis B virus (

187 -HBc), indicative of previous HBV infection; hepatitis B surface antigen (HBsAg), indicative of chron

188 ose with human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), prevalent hepatic d

189 variant became detectable shortly after the hepatitis B surface antigen (HBsAg), suggesting a correl

190 119E mutation impaired detection of secreted hepatitis B surface antigen (HBsAg), suggesting immune e

191 When couples with vaccination with hepatitis B surface antigen (HBsAg), the hormone, immuno

192 , IL-12p70, CXCL10 and subsequent decline in hepatitis B surface antigen (HBsAg), with 20% HBsAg loss

193 spective, multicenter trial and enrolled 118 hepatitis B surface antigen (HBsAg)- and hepatitis B e a

194 l groups: HBIg-treated patients who remained hepatitis B surface antigen (HBsAg)-negative (n = 4) and

195 us (HBV) infection (OBI), serum samples from hepatitis B surface antigen (HBsAg)-negative subjects <1

196 Hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)-negative, antibody t

197 The benefits of screening hepatitis B surface antigen (HBsAg)-positive carriers fo

198 Using kidneys from hepatitis B surface antigen (HBsAg)-positive donors is t

199 spective, multicenter, cohort study of 2,562 hepatitis B surface antigen (HBsAg)-positive individuals

200 in (HBIg) reduces the risk of reinfection in hepatitis B surface antigen (HBsAg)-positive liver trans

201 rate of HBV infection among children born to hepatitis B surface antigen (HBsAg)-positive mothers and

202 ased on findings from a prospective study of hepatitis B surface antigen (HBsAg)-positive patients, w

203 as detected by TaqMan in 164 of 195 (84%) of hepatitis B surface antigen (HBsAg)-positive samples.

204 on-years, respectively, among women who were hepatitis B surface antigen (HBsAg)-seronegative and HBs

205 This analysis included hepatitis B surface antigen (HBsAg)-seropositive and ant

206 with hepatitis B virus (HBV) eventually lose hepatitis B surface antigen (HBsAg).

207 ned as persistent HBV DNA without detectable hepatitis B surface antigen (HBsAg).

208 nfection and a laboratory record of positive hepatitis B surface antigen (HBsAg).

209 V) DNA in a serum or liver in the absence of hepatitis B surface antigen (HBsAg).

210 3 (p53-/-) and to transgenic mice expressing hepatitis B surface antigen (HBsAg).

211 tween HBV cccDNA, RNA, and expression of the hepatitis B surface antigen (HBsAg).

212 strategy: No pregnant women are screened for hepatitis B surface antigen (HBsAg).

213 isone) chemotherapy: screen all patients for hepatitis B surface antigen (HBsAg; Screen-All), screen

214 viewed our experience with liver grafts from hepatitis-B surface antigen (HBsAg)(-), antibody to core

215 homa patients with "resolved" HBV infection (hepatitis B surface antigen [HBsAg] negative and hepatit

216 nts either untreated (25) or NUC treated (36 hepatitis B surface antigen [HBsAg](+) and 10 HBsAg(-)/h

217 510A greatly reduced small envelope protein (hepatitis B surface antigen [HBsAg]) levels both inside

218 ating the request for a serological profile (hepatitis B surface antigen [HBsAg], anti-HBc, and anti-

219 mending screening for hepatitis B infection (hepatitis B surface antigen [HBsAg], antihepatitis B cor

220 fined HBV coinfection as a positive test for hepatitis B surface antigen, HBV DNA, or hepatitis B e a

221 spectively for human immunodeficiency virus, hepatitis B surface antigen, hepatitis C virus, and huma

222 tectable HBV DNA serum levels or antibody to hepatitis B surface antigen/hepatitis B surface antigen

223 Quantitative hepatitis B surface antigen in addition to other clinica

224 function and produced more serum albumin or hepatitis B surface antigen in deficient hosts.

225 dence of ongoing viral infection: persistent hepatitis B surface antigen in three (6%), HCV antibody

226 ts also responded to later vaccinations with hepatitis B surface antigen, indicating that no immunolo

227 HBV functional cure is sustained hepatitis B surface antigen loss and anti-HBs gain, with

228 The weighted probability of hepatitis B surface antigen loss was 2.0%.

229 , although rates of HBeAg seroconversion and hepatitis B surface antigen loss were low.

230 for liver injury (i.e., negative HCV RNA and hepatitis B surface antigen, low alcohol consumption, no

231 However, transgenic hepatitis B surface antigen mice, expressing hepatitis B

232 cy virus (HIV), hepatitis C virus (HCV), and hepatitis B surface antigen nearly tripled between 1 wee

233 The patient is clinically normal, serum hepatitis B surface antigen negative at 10 months of fol

234 ivation in patients with resolved infection (hepatitis B surface antigen negative) receiving chemothe

235 ere HBeAg negative at week 48 and one became hepatitis B surface antigen negative.

236 Serum samples from 400 hepatitis B surface antigen-negative organ donors were t

237 vious or occult HBV infection in a cohort of hepatitis B surface antigen-negative patients with histo

238 Hepatitis B virus infection originating from hepatitis B surface antigen-negative, hepatitis B core a

239 han genotype 1b, if they tested positive for hepatitis B surface antigen or anti-HIV antibody at scre

240 ze (OR, 1.23; 95% CI: 1.09-1.40; P = 0.001), hepatitis B surface antigen, or anti-hepatitis C virus p

241 sk among subjects with positive serology for hepatitis B surface antigen (P for trend = 0.02).

242 ERA plasmid DNA and a plasmid expressing the hepatitis B surface antigen (pCMV-s) by the i.m. route r

243 s part of an intradermal delivery system for hepatitis B surface antigen, PCPP demonstrates superior

244 developed de novo HBV: two recipients became hepatitis B surface antigen positive at 70 and 23 months

245 Stratified by HBV coinfection status (hepatitis B surface antigen positive at baseline), we de

246 eated patients who were HBV DNA negative but hepatitis B surface antigen positive had lower levels of

247 tigen positive) or partial (HBV DNA negative/hepatitis B surface antigen positive) control of their i

248 o had complete (HBV DNA negative/antibody to hepatitis B surface antigen positive) or partial (HBV DN

249 ) were HCV-antibody positive, 85 (7.4%) were hepatitis B surface antigen positive, and 17 (1.5%) were

250 luded the following: illicit drug use, serum hepatitis B surface antigen positive, grade 1 encephalop

251 The number of identified hepatitis B surface antigen-positive children <20 years

252 patitis B vaccine prophylaxis of newborns of hepatitis B surface antigen-positive mothers, were extra

253 ery during ART was significantly impaired in hepatitis B surface antigen-positive patients and in tho

254 tive EGC-HCC association became stronger for hepatitis B surface antigen-positive persons who also ha

255 Those who are found to be hepatitis B surface antigen-positive should start approp

256 val, 4.5%-7.1%) had dual infection with HBV (hepatitis B surface antigen-positive).

257 holic drinks per week (IRR, 1.68, P < .001), hepatitis B surface antigen positivity (IRR, 1.68, P < .

258 ng for age at HCV infection, past or current hepatitis B surface antigen positivity, and history of a

259 th human immunodeficiency virus coinfection, hepatitis B surface antigen positivity, cirrhosis, and H

260 ing those with human immunodeficiency virus, hepatitis B surface antigen positivity, hepatocellular c

261 This 120 kDa fusion protein between the hepatitis B surface antigen preS2 sequence and beta-gala

262 ization of the baboon fetus with recombinant hepatitis B surface antigen produced a specific fetal Ig

263 n dipeptidyl peptidase IV or from transgenic hepatitis B surface antigen-producing G26 mice with hepa

264 apy, the estimated overall seroprevalence of hepatitis B surface antigen remains high at 6.1% (95% un

265 plete HBV genome and the gene coding for the hepatitis B surface antigen (S gene) identified sequence

266 ges to the overlapping viral envelope of the hepatitis B surface antigen (sE164D, sI195M).

267 The cumulative rate of hepatitis B surface antigen seroclearance at 1, 5, and 1

268 Incidence rates of HBV infection and hepatitis B surface antigen seroclearance were estimated

269 ortion of chronic carriers, and the rates of hepatitis B surface antigen seroclearance.

270 Patients with positive anti-hepatitis B surface antigen serology were excluded.

271 Eighty percent of them were hepatitis B surface antigen seropositive.

272 l therapy reduced MTCT, as defined by infant hepatitis B surface antigen seropositivity (risk ratio =

273 ional adjustment for liver enzyme levels and hepatitis B surface antigen status (men: HR, 0.60; P tre

274 status, ascertained semiannually, and their hepatitis-B surface antigen status (HBsAg), which we asc

275 n wild-type mice, and in mice that carried a hepatitis B surface antigen transgene-this to model the

276 hepatitis B surface antigen mice, expressing hepatitis B surface antigen under control of the albumin

277 encoding the small envelope protein and that hepatitis B surface antigen was absent as well.

278 Antibody to hepatitis B surface antigen was tested 1 month after the

279 ositive patients lost hepatitis B e antigen; hepatitis B surface antigen was undetectable in 3 (6%);

280 onal cure characterized by sustained loss of hepatitis B surface antigen with or without hepatitis B